H-L Chen1, Y-T Tung2, C-L Tsai2, C-W Lai2, Z-L Lai2, H-C Tsai3, Y-L Lin4, C-H Wang5, C-M Chen6. 1. Department of Bioresources, Da-Yeh University, Changhwa, Taiwan. 2. Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan. 3. 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan [2] Department of Surgery, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan. 4. 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan [2] Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan. 5. Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan. 6. 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan [2] Rong Hsing Research Center for Translational Medicine and the iEGG Center, National Chung Hsing University, Taichung, Taiwan.
Abstract
OBJECTIVE: Fatty liver disease is commonly associated with obesity, insulin resistance and diabetes. Severe fatty liver is sometimes accompanied by steatohepatitis and may lead to the development of hepatocellular carcinoma. At present, there is no effective treatment for non-alcoholic fatty liver disease (NAFLD); thus, recent investigations have focused on developing effective therapeutics to treat this condition. This study aimed to evaluate the effects of kefir on the hepatic lipid metabolism of ob/ob mice, which are commonly used to model fatty liver disease. RESULTS: In this study, we used leptin receptor-deficient ob/ob mice as an animal disease model of NAFLD. Six-week-old ob/ob mice were orally administered the dairy product kefir (140 mg kg(-1) of body weight (BW) per day) for 4 weeks. The data demonstrated that kefir improved fatty liver syndrome on BW, energy expenditure and basal metabolic rate by inhibiting serum glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) activities (P<0.05) and by decreasing the triglyceride (TG) and total cholesterol (TC) contents of the liver (P<0.05). Oral kefir administration also significantly reduced the macrovesicular fat quantity in liver tissue. In addition, kefir markedly decreased the expression of the genes sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) (P<0.05) but not the expression of peroxisome proliferator-activated receptor α (PPARα) or hepatic carnitine palmitoyltransferase-1α (CPT1α) in the livers of ob/ob mice. CONCLUSION: On the basis of these results, we conclude that kefir improves NAFLD on BW, energy expenditure and basal metabolic rate by inhibiting the lipogenesis pathway and that kefir may have the potential for clinical application to the prevention or treatment of NAFLD.
OBJECTIVE:Fatty liver disease is commonly associated with obesity, insulin resistance and diabetes. Severe fatty liver is sometimes accompanied by steatohepatitis and may lead to the development of hepatocellular carcinoma. At present, there is no effective treatment for non-alcoholic fatty liver disease (NAFLD); thus, recent investigations have focused on developing effective therapeutics to treat this condition. This study aimed to evaluate the effects of kefir on the hepatic lipid metabolism of ob/ob mice, which are commonly used to model fatty liver disease. RESULTS: In this study, we used leptin receptor-deficient ob/ob mice as an animal disease model of NAFLD. Six-week-old ob/ob mice were orally administered the dairy product kefir (140 mg kg(-1) of body weight (BW) per day) for 4 weeks. The data demonstrated that kefir improved fatty liver syndrome on BW, energy expenditure and basal metabolic rate by inhibiting serum glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) activities (P<0.05) and by decreasing the triglyceride (TG) and total cholesterol (TC) contents of the liver (P<0.05). Oral kefir administration also significantly reduced the macrovesicular fat quantity in liver tissue. In addition, kefir markedly decreased the expression of the genes sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) (P<0.05) but not the expression of peroxisome proliferator-activated receptor α (PPARα) or hepatic carnitine palmitoyltransferase-1α (CPT1α) in the livers of ob/ob mice. CONCLUSION: On the basis of these results, we conclude that kefir improves NAFLD on BW, energy expenditure and basal metabolic rate by inhibiting the lipogenesis pathway and that kefir may have the potential for clinical application to the prevention or treatment of NAFLD.
Authors: Chuan-Mu Chen; Hsiao-Ling Chen; Timothy H-C Hsiau; Andrew H-A Hsiau; Huidong Shi; Graham J R Brock; Susan H Wei; Charles W Caldwell; Pearlly S Yan; Tim Hui-Ming Huang Journal: Am J Pathol Date: 2003-07 Impact factor: 4.307
Authors: Kristin M Hirahatake; Richard S Bruno; Bradley W Bolling; Christopher Blesso; Lacy M Alexander; Sean H Adams Journal: Adv Nutr Date: 2020-03-01 Impact factor: 8.701
Authors: Jennifer K Spinler; Aaron Brown; Caná L Ross; Prapaporn Boonma; Margaret E Conner; Tor C Savidge Journal: Anaerobe Date: 2016-05-11 Impact factor: 3.331